Sbir phase i topic 353: cfna tempo-SEQ assay
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201600059C
- Awardee
-
Biospyder Technologies, Inc. UEI KLCPP1J49GC5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $270,284
Award facts
- Opportunity
-
- PHS20161 Solicitation number
- Contract value 100% obligated
- $270,284.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 17 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Carlsbad, CA 92008, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $270,284 |
About this award
This is a $270,284.00 Firm Fixed Price Definitive Contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Biospyder Technologies, Inc., a small business manufacturer of genomic analysis services and products. The contract was awarded under the Small Business Innovation Research (SBIR) Phase I program for Topic 353: CFNA TEMPO-SEQ ASSAY, with a completion date of June 18, 2017.
Biospyder provides next-generation sequencing, bioinformatics analysis, and data management services for high-throughput transcriptomics of cell and tissue samples exposed to various compounds, leveraging its proprietary Tempo-Seq targeted gene expression technology. This contract supports Biospyder's efforts to advance its Tempo-Seq platform, which enables targeted RNA sequencing at scale for applications in toxicology, biomarker discovery, and other research areas. Biospyder has also received multiple grants from NIH institutes and federal research programs to further develop its gene expression profiling capabilities.
Quick answers
Who was awarded contract HHSN261201600059C?
HHSN261201600059C was awarded to Biospyder Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN261201600059C worth?
The government has obligated $270,284 on HHSN261201600059C.
Was contract HHSN261201600059C competed?
The extent of competition for HHSN261201600059C was full and open competition after exclusion of sources. The government received 17 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award